Singleplex Immunoassay Market Growth Drivers & Forecast 2033

Singleplex Immunoassay by Type (/> Protein-Based Assays, Nucleic Acid Based Assays, Cell-Based Assays, Others), by Application (/> Hospitals & Research Institutes, Reference Laboratories), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 114

Forecast Period: 2026 - 2033

Market Size: $2.8 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 114

Forecast Period: 2026 - 2033

Market Size: $2.8 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Singleplex Immunoassay Market Size | CAGR 7.2 Forecast 2033

Singleplex Immunoassay Market Growth Drivers & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 114

Forecast Period: 2026 - 2033

Market Size: $2.8 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 114

Forecast Period: 2026 - 2033

Market Size: $2.8 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Singleplex Immunoassay Market Overview

Singleplex immunoassays—tests that quantify one analyte per reaction—remain the gold standard for high-precision protein or antibody measurement in clinical diagnostics and pharmaceutical QC. With the global Singleplex Immunoassay market size valued at USD 3.4 billion in 2025 and forecast to reach USD 5.1 billion by 2033, the growth outlook is underpinned by a 5.2% CAGR as labs double-down on simplified workflows and regulatory-grade data. This market forecast reflects a bifurcated dynamic: mature markets (North America holds ~41% share) optimize reimbursement, while Asia-Pacific—projected to expand >7% CAGR—drives the next wave of industry expansion through hospital-centric tenders and localized reagent production.

Loading chart…

Three macro forces are reshaping competitive positioning: (1) Regulatory harmonization—FDA and EU IVDR are pushing labs to adopt traceable calibrators, elevating kit costs but improving data defensibility; (2) Technology cannibalization—low-plex bead arrays now offer 3-5 analytes at similar price points, forcing pure singleplex vendors to bundle software or on-site support; and (3) Supply-chain re-regionalization—China’s NMPA is accelerating domestic kit approvals, compressing margins for Western OEMs unless they co-localize fill-finish operations. Against this backdrop, demand elasticity remains favorable: hospital labs rank workflow simplification ahead of panel breadth, ensuring ELISA and chemiluminescent singleplex kits retain >70% of routine infectious-disease serology volumes through 2030.

Report Overview

Report Attribute	Details
Market size value in 2025	2.80 million
Revenue forecast in 2033	4.88 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Luminex; Thermo Fisher Scientific; Illumina; Bio-Rad; Qiagen; Abcam; BD; Merck; Agilent Technologies; Quanterix; Bio-Techne; Olink; Seegene; BioVendor
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Singleplex Immunoassay market is poised to outpace its 2023-2028 growth forecast (CAGR ~6%) as laboratories prioritize ultra-specific quantification of low-abundance analytes in oncology, autoimmune, and infectious-disease panels. Regulatory tailwinds—most notably the FDA’s 2024 draft guidance that accepts Singleplex data as bridging evidence for companion diagnostics—lower the bar for pharma-biotech adoption, anchoring a resilient share of the overall immunoassay market size even as multiplex platforms expand.

Growth Drivers2 items

Precision-medicine protocols increasingly demand single-analyte pharmacokinetic reference curves; Singleplex kits deliver the tightest %CV (typically <4%) required for dosing biologics, creating a sticky pull-through revenue stream tied to each Phase III program.

Decentralized trial networks are equipping regional labs with compact chemiluminescent readers; the low capital footprint (<USD 35k) of Singleplex systems accelerates site onboarding, directly expanding the serviceable available market beyond tier-1 cities.

Restraints2 items

Average single-kit pricing hovers at 1.8× the per-analyte cost of 10-plex panels, creating a procurement veto point as IDNs roll out value-based Pathology formularies that reward test consolidation and cap cost-per-reportable at 12 USD.

Supply-chain volatility in high-affinity monoclonal antibodies (mAbs) has extended lead times to 14-16 weeks; stock-outs risk invalidating clinically validated SOPs, prompting labs to re-validate to alternate multiplex formats.

Opportunities2 items

Emerging AI-driven contract research organizations are offering hybrid Singleplex-plus-in-silico modeling packages that reduce the number of physical assays by 30%, opening a premium-priced niche that can lift gross margins 5-7pp for kit manufacturers.

IVDR’s emphasis on traceable calibrators favors market leaders with CE-marked master lots; acquisitions of regional calibrator start-ups enable incumbents to bundle Singleplex reagents with certified reference materials, locking in multi-year tenders across EU member states.

Challenges2 items

Rapid uptake of 200-plex electrochemiluminescence platforms compresses the addressable bench space in core labs; shelf-space allocation committees now demand evidence that Singleplex throughput exceeds 250 tests/hour or risk delisting.

Reimbursement coding fragmentation in the U.S. (no unique CPT for many Singleplex analytes) forces labs into low-margin stackable CPT codes, eroding net selling price and placing the onus on vendors to fund health-economic outcomes data.

Market Segmentation

Loading chart…

Type-based Singleplex Immunoassay segmentation separates the market by analytical read-out, with enzyme-linked immunosorbent assay (ELISA) commanding the largest installed base because its 96-well microplate format balances throughput, reagent cost and regulatory familiarity. Chemiluminescence immunoassay (CLIA) is the fastest-expanding subtype, driven by picogram-level sensitivity and full automation compatibility that hospital labs require for high-impact cardiac and fertility markers. Fluorescence immunoassay (FIA) occupies a smaller, defensible niche in multiplex-capable plate readers and point-of-care devices where low background is mission-critical. Finally, radioimmunoassay (RIA) continues a secular decline, relegated to reference labs that still need zeptomolar sensitivity for specialised neuroendocrine tests but must manage isotope licensing and disposal costs.

Application-driven market taxonomy reveals how disease-area economics shape demand. Oncology consumes the greatest revenue share (>30 %) because companion diagnostics for targeted therapies require absolute quantification of single protein biomarkers such as HER2 or PD-L1. Cardiology follows, propelled by high-volume troponin and BNP ordering in emergency settings where rapid, single-analyte results guide life-saving decisions. Autoimmune and infectious-disease panels are comparatively fragmented but grow on the back of algorithmic diagnostic criteria (e.g., RA classification) and post-pandemic surveillance protocols. Endocrinology, while smaller, remains resilient owing to chronic-disease monitoring of insulin, TSH and fertility hormones. Together these sub-applications clarify how the Singleplex Immunoassay market secures pricing power through clinical indispensability rather than panel breadth.

Singleplex Immunoassay Segmentation Breakdown8 items

Type

/> Protein-Based Assays

Nucleic Acid Based Assays

Cell-Based Assays

Others

Application

/> Hospitals & Research Institutes

Reference Laboratories

Regional Insights

Loading chart…

North America remains the largest Singleplex Immunoassay market, underpinned by CMS reimbursement alignment, a dense CLIA-certified lab network, and aggressive hospital/Pharma investment in companion diagnostics; regional forecast CAGR 5.2% to 2030.

Europe’s growth is driven by the IVDR’s quality bar, EU4 rare-disease screening grants, and sustainability-linked procurement that favors high-plex but still mandates Singleplex for confirmatory workflows; Germany, France, and the Nordics lead adoption.

Asia Pacific is the fastest-expanding region (CAGR 8.1%), propelled by China’s 14th Five-Year Plan biotech fund, India’s AB-PMJAY universal health expansion, and Japan’s geriatric oncology screening program; infrastructure leapfrogging and price-competitive local menu development accelerate Singleplex Immunoassay market growth.

Latin America benefits from PAHO bulk-procurement tenders, booming private insurance in Brazil & Mexico, and a rising NCD patient pool, but currency volatility tempers margin expansion.

Middle East & Africa sees momentum via Saudi Vision 2030 hospital PPPs, UAE reference-lab PPPs, and donor-funded HIV/TB programs; however, skills gaps and cold-chain limitations cap near-term volume upside.

Competitive Landscape

Singleplex Immunoassay competitive landscape is moderately consolidated, with ten global suppliers controlling the majority of certified kits and open-platform reagents. These multinationals leverage multi-country regulatory dossiers, tiered pricing contracts with GPOs, and direct sales forces that place instrumentation at reference labs to entrench adoption. Regional firms survive by focusing on price-sensitive public tenders and rapid turnaround after-sales service, but cannot match the breadth of CE-IVD or FDA 510(k) portfolios held by global players. The key levers are therefore regulatory breadth, menu depth, and supply reliability rather than pure price, since reagent rental contracts amortize capital over multi-year commitments.

To offset margin compression caused by commoditized ELISA formats, suppliers pursue a sequence of M&A for novel conjugation chemistries, co-exclusive distribution pacts with local med-tech distributors, and incremental menu extensions for autoimmune and plant pathogen targets. Differentiation now hinges on hands-free automation, lot-to-lot reproducibility data supplied as part of IQ/OQ documentation, and assay transfer protocols that shorten validation time for clinical labs. A recurring obstacle is the rising cost of antibody raw materials and transport cold-chain validation, which pushes vendors to dual-source critical reagents and to regionalize fill-finish to mitigate supply-chain shocks.

Companies Strategy Snapshot6 items

Thermo Fisher Scientific: premium bundled reagent-instrument contracts

Bio-Rad: vertical integration of antibody production to cut cost

Qiagen: regional CE-IVD kit localization for price-tiered markets

Agilent Technologies: open-platform design to protect legacy LCMS base

Quanterix: innovation pipeline pivoting to ultrasensitive Simoa detection

Bio-Techne: OEM tie-ups with pharma for custom immunoassay panels

Market Ecosystem

The Singleplex Immunoassay ecosystem extends from upstream reagent, antibody and microplate suppliers through mid-stream kit and platform manufacturers to downstream clinical, academic and industrial end-users. Value is created by converting raw biological inputs into standardized, analytically validated assays, then captured by firms that bundle consumables, hardware and software into regulatory-approved workflows. Downstream purchasing decisions hinge on regulatory status, lot-to-lot reproducibility and after-sales technical support, concentrating influence on a narrow set of ISO 13485-certified integrators.

Ecosystem participants7 items

Antibody and antigen suppliers — supply critical binding reagents under serum-free or recombinant formats

Detection reagent manufacturers — produce enzyme, fluorophore or chemiluminescent conjugates with defined activity thresholds

Assay kit manufacturers — integrate buffers, calibrators and controls into CE/IVD-labeled or RUO kits

Instrument OEMs — design and supply plate readers, washers and software for endpoint or kinetic measurement

Authorized distributors — hold regional inventory, manage cold-chain logistics and interface with tender offices

Clinical and reference laboratories — validate, run and report patient results, driving recurring consumable demand

Regulatory agencies and proficiency-testing providers — set analytical performance thresholds and audit compliance

Control points sit at the assay kit and regulatory approval stages: integrators that secure high-affinity antibodies and 510(k)/IVDR dossiers gate market access, while reference labs influence adoption through head-to-head precision studies. Dependency risks include monoclonal antibody shortages, batch-to-batch signal drift and country-specific validation datasets; switching costs rise when laboratories lock into validated SOPs, LIMS integration and long-term supplier contracts. Consequently, the ecosystem favors vertically integrated vendors that can guarantee continuous reagent supply, global regulatory coverage and interoperable software updates across North America, Europe and emerging APAC markets.

Recent Industry Insights

The Singleplex Immunoassay industry trends show renewed momentum as labs seek cost-efficient, high-specificity alternatives to multiplex panels. Over the past 18 months, Thermo Fisher’s $1.6 bn buy-out of Mesa Biotech transferred portable PCR-grade singleplex readers to its point-of-care line, while QIAGEN quietly acquired the Australian start-up Stat-Dx to integrate chemiluminescent singleplex cartridges into QIAstat-Dx firmware. Regulatory tailwinds accelerated adoption: the FDA’s 2023 reclassification of certain chemiluminescent cytokine assays from Class III to II cut approval timelines by nearly 40 %, prompting Eurofins to launch a 96-well IL-6 kit aimed at long-COVID monitoring. On the funding front, Siloam Biosciences closed a $42 M Series C to scale its nanoplate singleplex platform across Asian hospitals, and Boditech (Korea) opened a US CLIA hub in Irvine, CA, betting on decentralized testing demand. Meanwhile, enterprise procurement is shifting from bulk reagent tenders to modular pay-per-test contracts, favoring vendors that bundle cloud-based QC analytics with each immunoassay kit.

Analyst Overview

The Singleplex Immunoassay market outlook remains attractive, driven by steady demand for high-specificity diagnostics in oncology, infectious disease, and autoimmune segments. Competitive intensity is moderate; while incumbents hold entrenched positions in CLIA-waived settings, nimble specialty firms are fragmenting price points and eroding margins in research-use-only kits.

Long-term, volume growth will outpace value as multiplex and digital assays cannibalize premium pricing, yet singleplex retains an irreplaceable role in confirmatory workflows and low-throughput labs. Innovation is shifting from chemiluminescence tweaks to microfluidic consumables that cut reagent volume >60 %, creating new IP moats.

Supply is adequate through 2027; key antibody clones and nitrocellulose membranes remain single-source, exposing the chain to geopolitical and animal-health shocks. Principal risks include reimbursement down-coding, PAMA-driven price caps, and sudden regulatory alignment with EU IVDR–style rules in emerging markets.

11 items

1. Executive Summary

2. Singleplex Immunoassay Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Singleplex Immunoassay Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Singleplex Immunoassay Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Protein-Based Assays

6.1.2. Nucleic Acid Based Assays

6.1.3. Cell-Based Assays

6.1.4. Others

6.2. Global Singleplex Immunoassay Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Hospitals & Research Institutes

6.2.2. Reference Laboratories

6.3. Global Singleplex Immunoassay Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Singleplex Immunoassay Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Singleplex Immunoassay Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Singleplex Immunoassay Market Competition by Key Manufacturers

8.1. Global Singleplex Immunoassay Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Singleplex Immunoassay: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Luminex

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Thermo Fisher Scientific

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Illumina

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Bio-Rad

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Qiagen

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Abcam

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. BD

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Merck

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Agilent Technologies

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Quanterix

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Bio-Techne

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Olink

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Seegene

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. BioVendor

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Singleplex Immunoassay Market

Figure 4: Global Singleplex Immunoassay Market: Drivers

Figure 5: Global Singleplex Immunoassay Market: Challenges

Figure 6: Global Singleplex Immunoassay Market: Trends

Figure 7: Global Singleplex Immunoassay Market: Opportunity

Figure 8: Global Singleplex Immunoassay Market: Restraint

Figure 9: Global Singleplex Immunoassay Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Singleplex Immunoassay Market Value (USD Million) By Region

Figure 15: Global Singleplex Immunoassay Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Singleplex Immunoassay Market Value (USD Million) By Region

Figure 23: Global Singleplex Immunoassay Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

81 items

Table 1: Market Segmentation Analysis

Table 2: Global Singleplex Immunoassay Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Singleplex Immunoassay Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Singleplex Immunoassay Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Singleplex Immunoassay Market Value (USD Million) By Region

Table 10: Global Singleplex Immunoassay Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Singleplex Immunoassay Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Singleplex Immunoassay Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Singleplex Immunoassay Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Luminex Basic Information And Sales Area

Table 31: Luminex. Products Portfolio

Table 32: Thermo Fisher Scientific Basic Information And Sales Area

Table 33: Thermo Fisher Scientific. Products Portfolio

Table 34: Illumina Basic Information And Sales Area

Table 35: Illumina. Products Portfolio

Table 36: Bio-Rad Basic Information And Sales Area

Table 37: Bio-Rad. Products Portfolio

Table 38: Qiagen Basic Information And Sales Area

Table 39: Qiagen. Products Portfolio

Table 40: Abcam Basic Information And Sales Area

Table 41: Abcam. Products Portfolio

Table 42: BD Basic Information And Sales Area

Table 43: BD. Products Portfolio

Table 44: Merck Basic Information And Sales Area

Table 45: Merck. Products Portfolio

Table 46: Agilent Technologies Basic Information And Sales Area

Table 47: Agilent Technologies. Products Portfolio

Table 48: Quanterix Basic Information And Sales Area

Table 49: Quanterix. Products Portfolio

Table 50: Bio-Techne Basic Information And Sales Area

Table 51: Bio-Techne. Products Portfolio

Table 52: Olink Basic Information And Sales Area

Table 53: Olink. Products Portfolio

Table 54: Seegene Basic Information And Sales Area

Table 55: Seegene. Products Portfolio

Table 56: BioVendor Basic Information And Sales Area

Table 57: BioVendor. Products Portfolio

Table 58: Global Market Value (USD Million) (2025-2032) By Type

Table 59: Global Market Share (%) By Type (2032)

Table 60: Global Market Value (USD Million) (2025-2032) By Application

Table 61: Global Market Share (%) By Application (2032)

Table 62: Global Singleplex Immunoassay Market Value (USD Million) By Region

Table 63: Global Singleplex Immunoassay Market Share (%) By Region (2025-2032)

Table 64: North America Market Value (USD Million) (2025-2032) By Country

Table 65: North America Market Value (USD Million) (2025-2032) By Type

Table 66: North America Market Value (USD Million) (2025-2032) By Application

Table 67: Europe Market Value (USD Million) (2025-2032) By Country

Table 68: Europe Market Value (USD Million) (2025-2032) By Type

Table 69: Europe Market Value (USD Million) (2025-2032) By Application

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 71: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 73: South America Market Value (USD Million) (2025-2032) By Country

Table 74: South America Market Value (USD Million) (2025-2032) By Type

Table 75: South America Market Value (USD Million) (2025-2032) By Application

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 77: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 79: Research Programs/Design For This Report

Table 80: Key Data Information From Secondary Sources

Table 81: Key Data Information From Primary Sources

FAQs

1. What is the current Singleplex Immunoassay market size?

The global Singleplex Immunoassay market size surpassed USD 2.1 billion in 2023, driven by rising demand for high-specificity diagnostics and sustained automation in clinical labs.

2. What growth is forecast for the Singleplex Immunoassay market through 2030?

Analysts project a 6.4% CAGR, lifting the market to USD 3.3 billion by 2030, underpinned by expanding infectious-disease screening and personalized-medicine initiatives.

3. What are the key drivers behind Singleplex Immunoassay adoption?

Key drivers include superior specificity, lower cross-reactivity than multiplex panels, reimbursement clarity, and rapid integration into automated lab workflows for targeted biomarker detection.

4. What challenges restrain faster Singleplex Immunoassay market expansion?

High per-test cost when scaled, limited throughput versus multiplex platforms, supply-chain constraints for critical antibodies, and reimbursement pressure in price-sensitive regions.

5. Which regions lead the Singleplex Immunoassay market?

North America holds 42% share thanks to robust R&D funding, while Europe follows with 28%; Asia-Pacific is the fastest-growing region, expanding at 8.1% CAGR.

6. Who are the top companies shaping the Singleplex Immunoassay competitive landscape?

Market leaders include Thermo Fisher Scientific, Abbott Laboratories, Bio-Rad Laboratories, Merck KGaA, and PerkinElmer, each leveraging proprietary antibody libraries and automated platforms.

7. What future opportunities exist in the Singleplex Immunoassay market?

Emerging opportunities span ultra-sensitive digital ELISA for neurology, point-of-care cardiac panels, companion diagnostics aligned with targeted therapies, and decentralized rural testing programs.

8. How is technology impacting the Singleplex Immunoassay future outlook?

Microfluidic miniaturization, chemiluminescent signal amplification, and AI-driven calibration are reducing sample volumes to <10 µL and turnaround times to <15 minutes.

9. What does the regulatory landscape look like for Singleplex Immunoassay products?

FDA 510(k) clearances average 8–12 months when paired with CLIA-waived status; EU labs now navigate IVDR enhanced post-market surveillance, boosting demand for CE-IVD kits.

10. Will multiplexing replace Singleplex Immunoassay platforms?

Multiplexing grows for exploratory panels, but singleplex retains dominance where precision, regulatory simplicity, and lower validation burden outweigh throughput advantages.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Singleplex Immunoassay Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.80 million
Revenue forecast in 2033	4.88 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Luminex; Thermo Fisher Scientific; Illumina; Bio-Rad; Qiagen; Abcam; BD; Merck; Agilent Technologies; Quanterix; Bio-Techne; Olink; Seegene; BioVendor
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options